A.T. van Oosterom

Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924

Cora N. Sternberg, P.H.M. de Mulder, Jan H. Schornagel et al. · Journal of Clinical Oncology · 2001 · 628 citations

Medicine, Oncology, Pharmacology +13

Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study

M. van Glabbeke, A.T. van Oosterom, J. Wolter Oosterhuis et al. · Journal of Clinical Oncology · 1999 · 570 citations

Medicine, Oncology, Pharmacology +16

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours

Cora N. Sternberg, PHM de Mulder, Jan H. Schornagel et al. · European Journal of Cancer · 2005 · 545 citations

Medicine, Oncology, Urology +9

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

Maria Dêbiec‐Rychter, Herlinde Dumez, Ian Judson et al. · European Journal of Cancer · 2004 · 442 citations

Medicine, Molecular Medicine, Oncology +14

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

René Bruno, Darcy A. Hille, A. Riva et al. · Journal of Clinical Oncology · 1998 · 423 citations

Pharmacy, Pharmacokinetics, Pharmacology +17